We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Guidant Issues Warning on Pacemakers

By HospiMedica staff writers
Posted on 27 Jul 2005
To limit adverse events, Guidant Corp. More...
(Indianapolis, IN, USA) has initiated communications to doctors worldwide regarding potential problems with the company's pacemakers.

The pacemakers in question are of an earlier generation design and have not been sold or implanted for four years. These devices are sold under the following names: Pulsar Max, Pulsar, Discovery, Meridian, Pulsar Max II, Discovery II, Virtus Plus II, Intelis II, and Contak TR. Guidant has determined that a hermetic sealing component in these devices may experience a gradual degradation, resulting in a higher-than-normal moisture content within the pacemaker case late in the device's life.

As of July 11, 2005, Guidant had identified 69 devices that may have exhibited this failure mode, out of a total of 78,000 devices distributed with this component. While no failures have been reported prior to 44 months of service, the likelihood of occurrence increases with implant time. Based on field experience, Guidant estimates the rate of failure in the remaining active implanted devices to be between 0.17% and 0.51% over the remaining device lifetime.

In deciding the best course of action, Guidant recommends that doctors consider the unique needs of individual patients. The company recommends that doctors consider replacing devices for pacemaker-dependent patients. Many of the devices are nearing or have exceeded their estimated longevity and have thus outlived their warranty. Guidant will provide a replacement device at no charge for pacemaker-dependent patients and others deemed by their doctors to best served by replacement. Only several weeks ago, Guidant was forced to announce recalls of certain of its implantable defibrillators.

"The health and safety of patients is paramount,” stated Ronald W. Dollens, president and CEO, Guidant Corp.




Related Links:
Guidant

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Pulmonary Ventilator
OXYMAG
Gynecological Examination Chair
arco-matic
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.